Jacobs Levy Equity Management Inc. Buys Shares of 1,033,763 Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Jacobs Levy Equity Management Inc. acquired a new stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,033,763 shares of the company's stock, valued at approximately $519,000. Jacobs Levy Equity Management Inc. owned approximately 0.47% of Lineage Cell Therapeutics at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Fort Sheridan Advisors LLC increased its position in Lineage Cell Therapeutics by 71.5% during the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company's stock worth $28,000 after buying an additional 23,000 shares in the last quarter. Atria Wealth Solutions Inc. purchased a new position in Lineage Cell Therapeutics during the fourth quarter worth $29,000. HighTower Advisors LLC increased its position in Lineage Cell Therapeutics by 49.5% during the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company's stock worth $29,000 after buying an additional 19,100 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Lineage Cell Therapeutics by 35.5% during the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company's stock worth $35,000 after purchasing an additional 18,053 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Lineage Cell Therapeutics by 33.0% during the fourth quarter. Wells Fargo & Company MN now owns 94,894 shares of the company's stock worth $48,000 after purchasing an additional 23,527 shares during the last quarter. Hedge funds and other institutional investors own 62.47% of the company's stock.

Lineage Cell Therapeutics Trading Up 15.6%

Lineage Cell Therapeutics stock traded up $0.09 during midday trading on Friday, hitting $0.70. The stock had a trading volume of 2,394,869 shares, compared to its average volume of 1,312,948. The stock has a market cap of $154.01 million, a P/E ratio of -5.82 and a beta of 1.21. Lineage Cell Therapeutics, Inc. has a 12 month low of $0.37 and a 12 month high of $1.15. The business has a fifty day moving average price of $0.47 and a 200 day moving average price of $0.62.

Analysts Set New Price Targets

LCTX has been the topic of several analyst reports. D. Boral Capital restated a "buy" rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Finally, B. Riley reduced their target price on Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a report on Friday, March 14th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $4.20.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.